Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients.
Tracking how cancer cells die during radiation therapy in patients' blood may help doctors predict treatment success and adjust plans in real time.
This prospective study in 71 metastatic lung and breast cancer patients receiving radiotherapy demonstrated that the apoptotic rate of circulating tumor cells (CTCs) before and after treatment is a powerful indicator of poor prognosis and correlates with RT response. The study establishes a minimally invasive liquid biopsy approach to real-time RT monitoring using CTC viability kinetics rather than CTC count alone.
What the study was
- Study design
- Prospective observational study
- Population
- Lung (n=35) and breast (n=36) cancer patients receiving radiotherapy for brain/bone metastases
- Sample size
- 71
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Molecular Oncology
Why it surfaced
CTC apoptotic rate as RT response biomarker is a meaningful novel contribution; prospective design with two cancer types strengthens generalizability; n=71 limits statistical power for subset analyses.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.